Prime Medicine Announces $125 Million Public Offering at $3.50 Per Share
Biotechnology company Prime Medicine (PRME) has priced a public offering of 35.7 million shares of common stock at $3.50 per share. The offering is expected to generate approximately $125 million in gross proceeds. The underwriters for the transaction have been granted a 30-day option to purchase up to an additional amount of shares. This capital raise provides the company with significant liquidity to support its ongoing operations and development programs.